Cargando…
Analytical validation of the 7-gene biosignature for prediction of recurrence risk and radiation therapy benefit for breast ductal carcinoma in situ
PURPOSE: Ductal carcinoma in situ (DCIS), is a noninvasive breast cancer, representing 20-25% of breast cancer diagnoses in the USA. Current treatment options for DCIS include mastectomy or breast-conserving surgery (BCS) with or without radiation therapy (RT), but optimal risk-adjusted treatment se...
Autores principales: | Dabbs, David, Mittal, Karuna, Heineman, Scott, Whitworth, Pat, Shah, Chirag, Savala, Jess, Shivers, Steven C., Bremer, Troy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236475/ https://www.ncbi.nlm.nih.gov/pubmed/37274253 http://dx.doi.org/10.3389/fonc.2023.1069059 |
Ejemplares similares
-
Prognostic Risk Assessment and Prediction of Radiotherapy Benefit for Women with Ductal Carcinoma In Situ (DCIS) of the Breast, in a Randomized Clinical Trial (SweDCIS)
por: Wärnberg, Fredrik, et al.
Publicado: (2021) -
The Clinical Utility of DCISionRT(®) on Radiation Therapy Decision Making in Patients with Ductal Carcinoma In Situ Following Breast-Conserving Surgery
por: Shah, Chirag, et al.
Publicado: (2021) -
Exoplanet Biosignatures: Understanding Oxygen as a Biosignature in the Context of Its Environment
por: Meadows, Victoria S., et al.
Publicado: (2018) -
Metabolic Processes Preserved as Biosignatures in Iron-Oxidizing Microorganisms: Implications for Biosignature Detection on Mars
por: Floyd, Melissa A. Merrill, et al.
Publicado: (2019) -
Nonphotosynthetic Pigments as Potential Biosignatures
por: Schwieterman, Edward W., et al.
Publicado: (2015)